An article in the March edition of Vaccine explains why it is necessary to know the background rates of possible Adverse Events of Special Interest (AESI) when monitoring the safety of COVID-19 vaccines. The article provides examples to illustrate the use of background rates and discusses tools available from the Brighton Collaboration that facilitate case evaluation and understanding of AESI.
- The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety April 17, 2021
- The UK Expert Haematology Panel (EHP) has produced guidance on the syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus vaccination April 8, 2021
- Why is it so hard to investigate the rare side effects of COVID vaccines? April 7, 2021
- Protocol template for cohort event monitoring (CEM) for safety signal detection after vaccination with COVID-19 vaccines March 30, 2021
- COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets March 20, 2021